

Anti-FGFR2/CD332 Antibody (Bemarituzumab)

Introduction

Bemarituzumab is a first-in-class humanized IgG1 monoclonal antibody directed against FGFR2b, a FGF receptor. Bemarituzumab prevents fibroblast growth factor from binding and activating FGFR2b. Bemarituzumab has the potential to be used in cancer research.

Product parameters

Alternative Names	HGS1036, HGS 1036, FP-1039
Target Accession	P21802
Target	FGFR2 / CD332
CAS number	1952272-74-0
Molecular Weight	144 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	SNU-16 cells were stained with Anti-FGFR2/CD332 Antibody (Bemarituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.5368 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

